DexCom, Inc. (DXCM) |
| 63.98 2.75 (4.49%) 04-17 16:00 |
| Open: | 62.43 |
| High: | 64.08 |
| Low: | 61.9 |
| Volume: | 5,864,435 |
| Market Cap: | 24,953(M) |
| PE Ratio: | 30.61 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 68.76 |
| Resistance 1: | 65.63 |
| Pivot price: | 63.08 |
| Support 1: | 60.57 |
| Support 2: | 50.39 |
| 52w High: | 89.98 |
| 52w Low: | 54.11 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| EPS | 2.090 |
| Book Value | 7.140 |
| PEG Ratio | 0.00 |
| Gross Profit | 7.275 |
| Profit Margin (%) | 17.94 |
| Operating Margin (%) | 25.64 |
| Return on Assets (ttm) | 8.9 |
| Return on Equity (ttm) | 34.5 |
Sat, 18 Apr 2026
DexCom, Inc. $DXCM Shares Purchased by Moran Wealth Management LLC - MarketBeat
Sat, 18 Apr 2026
KBC Group NV Sells 133,500 Shares of DexCom, Inc. $DXCM - MarketBeat
Sat, 18 Apr 2026
Chicago Capital LLC Reduces Position in DexCom, Inc. $DXCM - MarketBeat
Fri, 17 Apr 2026
A Look at DexCom Inc (DXCM) After 4.5% Gain -- GF Value $109.11 vs Price $63.98 - GuruFocus
Thu, 16 Apr 2026
Dexcom (DXCM) EVP sells 1,700 shares, still holds 111,204 - Stock Titan
Thu, 16 Apr 2026
Here's Why You Should Add DexCom Stock to Your Portfolio Now - TradingView — Track All Markets
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |